Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression changes caused by treatment of A375 cells with A-366 versus DMSO (vehicle)

ABSTRACT: Gene expression changes caused by treatment of A375 cells with A-366 versus DMSO (vehicle)

PROVIDER: PRJNA792397 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17332524.fastq.gz	Fastqsanger.gz
	SRR17332525.fastq.gz	Fastqsanger.gz
	SRR17332526.fastq.gz	Fastqsanger.gz
	SRR17332527.fastq.gz	Fastqsanger.gz
	SRR17332528.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Gene expression changes caused by treatment of A375 cells with A-366 versus DMSO (vehicle)

Project description:We use RNAseq to examine gene expression changes in A375 cells after treatment with A-366 versus DMSO (vehicle) of mScarlet tagged H3.3(wildtype) vs. H3.3(K9M)

2022-01-02 | GSE192612 | GEO

Gene expression changes caused by treatment of A375 cells with A-366 versus DMSO (vehicle)

Project description:Gene expression changes caused by treatment of A375 cells with A-366 versus DMSO (vehicle)

| PRJNA792397 | ENA

Human A375 melanoma cell line treated with ciclopirox and crizotinib

Project description:To generate drug signatures in human A375 melanoma cell lines. A375 cell line was plated at 4 x 105 cells/mL overnight and treated with ciclopirox or crizotinib at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59340 | GEO

Human A375 melanoma cell line treated with trifluorothymidine (TFT) and lactimidomycin (LTM)

Project description:To generate drug signatures in human A375 melanoma cell lines. A375 cell line was plated at 4 x 105 cells/mL overnight and treated with trifluridine or lactimidomycin at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59183 | GEO

Expression data from BRAFV600E A375 melanoma cells treated with vehicle or vemurafenib

Project description:Vemurafenib is a BRAF inhibitor with specificity for the most common BRAF mutant encountered in melanomas (BRAFV600E). Vemurafenib suppresses the proliferation of BRAF mutant human melanoma cells by suppressing downstream activation of the MEK/ERK mitogen activated protein kinases. We used microarrays to examine the transcriptional response of a vemurafenib-sensitive BRAFV600E human melanoma cell line (A375) to vemurafenib in order to further delineate the mechanisms by which BRAFV600E drives cell proliferation and energy metabolism in human melanoma. BRAFV600E A375 human melanoma cells were treated with vehicle (0.1% DMSO) or 10 uM vemurafenib for 24 h after which total RNA was extracted. Cells were prepared and RNA was extracted in 3 separate batches (three different cell stocks on three separate days) providing three independent replicates (n=3). Paired replicates (prepared from the same stock of cells on the same day) are denoted by A, B and C.

2014-05-20 | E-GEOD-42872 | biostudies-arrayexpress

Study the differential gene expression in A375 cells treated with DMSO or XL413 or GSK343 or GSK343 and XL413 combination

Project description:The study evaluated the differential gene expression in A375 cells treated with DMSO when compared to XL413 or GSK343 or GSK343 and XL413 combination using RNA-seq

2022-08-10 | GSE186276 | GEO

Study the differential gene expression in A375 cells treated with DMSO or XL413 or OF1 or OF1 and XL413 combination.

Project description:The study evaluated the differential gene expression in A375 cells treated with DMSO when compared to XL413 or OF1 or OF1 and XL413 combination using RNA-seq

2022-08-10 | GSE185976 | GEO

LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

Project description:LX-2 cells were pretreated with CM272 (400nM) or vehicle (0.01%DMSO) for 24 hours followed by incubation of TGFβ1 (5ng/ml) for another 24 hours.

2019-10-29 | GSE139504 | GEO

Expression data of A375 melanoma cells after DMSO or MLN4924 +/- Nutlin treatment for 26 hours

Project description:Microarrays were used to determine the change in gene expression of genes involved in the p53 pathway after siRNA knock down of p53, CDT1 or BRCA1 A375 cells were grown, transfected with siRNA, incubated for 48hrs, then incubated for another 26hrs in the presence of either 0.065% DMSO as control, 650nM MLN4924, 5uM Nutlin or 100nM Daunorubicin. RNA extraction and hybridization on Affymetrix HG-U133Plus 2.0 arrays were performed.

2012-07-04 | GSE39091 | GEO

FOXO-inhibited iPSC-derived cardiomyocytes compared against DMSO vehicle controls.

Project description:Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes cultured in 3-dimensional suspension culture were treated with AS1842856 FOXO-inhibitor (n=3 independent wells) or DMSO vehicle control (n=3 independent wells). Total RNA was isolated from each well and utilized for RNA sequencing.

2024-08-09 | GSE252627 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data